Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: From the look AHEAD study

Ligia Belalcazar, Steven M. Haffner, Wei Lang, Ron C. Hoogeveen, Julia Rushing, Dawn C. Schwenke, Russell P. Tracy, F. Xavier Pi-Sunyer, Andrea M. Kriska, Christie M. Ballantyne

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objective: Cardiovascular risk remains high despite statin use. Overweight/obese diabetic persons usually have normal/low LDL-cholesterol but high C-reactive protein (CRP) levels. We aimed to examine the effects of intensive lifestyle intervention for weight loss (ILI) on CRP levels in overweight/obese diabetic individuals by statin use. Design and Methods: Look AHEAD was a randomized trial in overweight/obese type 2 diabetic individuals testing whether ILI would reduce cardiovascular mortality, when compared to usual care. CRP changes in 1,431 participants with biomarker levels, who remained on or off statin treatment for 1 year, were evaluated. Results: The reduction in CRP levels with ILI at 1 year in men and women on statins was -44.9 and -42.3%, respectively, compared to -13.7 and -21.0% for those on statins and usual care (P < 0.0001). At 1 year, median CRP levels were: 1.8 mg L -1 in participants randomized to ILI on statin therapy; 2.6 mg L -1 for those on statins randomized to usual care and 2.9 mg L -1 for participants not on statins but randomized to ILI. Weight loss was associated with 1-year CRP reduction (P < 0.0001) in statin and nonstatin users. Conclusions: Our findings suggest that in overweight/obese diabetic persons, ILI and statin therapy may have substantial additive anti-inflammatory benefits.

Original languageEnglish (US)
Pages (from-to)944-950
Number of pages7
JournalObesity
Volume21
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
C-Reactive Protein
Type 2 Diabetes Mellitus
Life Style
Weight Loss
LDL Cholesterol
Anti-Inflammatory Agents
Therapeutics
Biomarkers

ASJC Scopus subject areas

  • Endocrinology
  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

Belalcazar, L., Haffner, S. M., Lang, W., Hoogeveen, R. C., Rushing, J., Schwenke, D. C., ... Ballantyne, C. M. (2013). Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: From the look AHEAD study. Obesity, 21(5), 944-950. https://doi.org/10.1002/oby.20431

Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes : From the look AHEAD study. / Belalcazar, Ligia; Haffner, Steven M.; Lang, Wei; Hoogeveen, Ron C.; Rushing, Julia; Schwenke, Dawn C.; Tracy, Russell P.; Pi-Sunyer, F. Xavier; Kriska, Andrea M.; Ballantyne, Christie M.

In: Obesity, Vol. 21, No. 5, 05.2013, p. 944-950.

Research output: Contribution to journalArticle

Belalcazar, L, Haffner, SM, Lang, W, Hoogeveen, RC, Rushing, J, Schwenke, DC, Tracy, RP, Pi-Sunyer, FX, Kriska, AM & Ballantyne, CM 2013, 'Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: From the look AHEAD study', Obesity, vol. 21, no. 5, pp. 944-950. https://doi.org/10.1002/oby.20431
Belalcazar, Ligia ; Haffner, Steven M. ; Lang, Wei ; Hoogeveen, Ron C. ; Rushing, Julia ; Schwenke, Dawn C. ; Tracy, Russell P. ; Pi-Sunyer, F. Xavier ; Kriska, Andrea M. ; Ballantyne, Christie M. / Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes : From the look AHEAD study. In: Obesity. 2013 ; Vol. 21, No. 5. pp. 944-950.
@article{16df5be5521c42169898c5c843e8a1ed,
title = "Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: From the look AHEAD study",
abstract = "Objective: Cardiovascular risk remains high despite statin use. Overweight/obese diabetic persons usually have normal/low LDL-cholesterol but high C-reactive protein (CRP) levels. We aimed to examine the effects of intensive lifestyle intervention for weight loss (ILI) on CRP levels in overweight/obese diabetic individuals by statin use. Design and Methods: Look AHEAD was a randomized trial in overweight/obese type 2 diabetic individuals testing whether ILI would reduce cardiovascular mortality, when compared to usual care. CRP changes in 1,431 participants with biomarker levels, who remained on or off statin treatment for 1 year, were evaluated. Results: The reduction in CRP levels with ILI at 1 year in men and women on statins was -44.9 and -42.3{\%}, respectively, compared to -13.7 and -21.0{\%} for those on statins and usual care (P < 0.0001). At 1 year, median CRP levels were: 1.8 mg L -1 in participants randomized to ILI on statin therapy; 2.6 mg L -1 for those on statins randomized to usual care and 2.9 mg L -1 for participants not on statins but randomized to ILI. Weight loss was associated with 1-year CRP reduction (P < 0.0001) in statin and nonstatin users. Conclusions: Our findings suggest that in overweight/obese diabetic persons, ILI and statin therapy may have substantial additive anti-inflammatory benefits.",
author = "Ligia Belalcazar and Haffner, {Steven M.} and Wei Lang and Hoogeveen, {Ron C.} and Julia Rushing and Schwenke, {Dawn C.} and Tracy, {Russell P.} and Pi-Sunyer, {F. Xavier} and Kriska, {Andrea M.} and Ballantyne, {Christie M.}",
year = "2013",
month = "5",
doi = "10.1002/oby.20431",
language = "English (US)",
volume = "21",
pages = "944--950",
journal = "Obesity",
issn = "1930-7381",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes

T2 - From the look AHEAD study

AU - Belalcazar, Ligia

AU - Haffner, Steven M.

AU - Lang, Wei

AU - Hoogeveen, Ron C.

AU - Rushing, Julia

AU - Schwenke, Dawn C.

AU - Tracy, Russell P.

AU - Pi-Sunyer, F. Xavier

AU - Kriska, Andrea M.

AU - Ballantyne, Christie M.

PY - 2013/5

Y1 - 2013/5

N2 - Objective: Cardiovascular risk remains high despite statin use. Overweight/obese diabetic persons usually have normal/low LDL-cholesterol but high C-reactive protein (CRP) levels. We aimed to examine the effects of intensive lifestyle intervention for weight loss (ILI) on CRP levels in overweight/obese diabetic individuals by statin use. Design and Methods: Look AHEAD was a randomized trial in overweight/obese type 2 diabetic individuals testing whether ILI would reduce cardiovascular mortality, when compared to usual care. CRP changes in 1,431 participants with biomarker levels, who remained on or off statin treatment for 1 year, were evaluated. Results: The reduction in CRP levels with ILI at 1 year in men and women on statins was -44.9 and -42.3%, respectively, compared to -13.7 and -21.0% for those on statins and usual care (P < 0.0001). At 1 year, median CRP levels were: 1.8 mg L -1 in participants randomized to ILI on statin therapy; 2.6 mg L -1 for those on statins randomized to usual care and 2.9 mg L -1 for participants not on statins but randomized to ILI. Weight loss was associated with 1-year CRP reduction (P < 0.0001) in statin and nonstatin users. Conclusions: Our findings suggest that in overweight/obese diabetic persons, ILI and statin therapy may have substantial additive anti-inflammatory benefits.

AB - Objective: Cardiovascular risk remains high despite statin use. Overweight/obese diabetic persons usually have normal/low LDL-cholesterol but high C-reactive protein (CRP) levels. We aimed to examine the effects of intensive lifestyle intervention for weight loss (ILI) on CRP levels in overweight/obese diabetic individuals by statin use. Design and Methods: Look AHEAD was a randomized trial in overweight/obese type 2 diabetic individuals testing whether ILI would reduce cardiovascular mortality, when compared to usual care. CRP changes in 1,431 participants with biomarker levels, who remained on or off statin treatment for 1 year, were evaluated. Results: The reduction in CRP levels with ILI at 1 year in men and women on statins was -44.9 and -42.3%, respectively, compared to -13.7 and -21.0% for those on statins and usual care (P < 0.0001). At 1 year, median CRP levels were: 1.8 mg L -1 in participants randomized to ILI on statin therapy; 2.6 mg L -1 for those on statins randomized to usual care and 2.9 mg L -1 for participants not on statins but randomized to ILI. Weight loss was associated with 1-year CRP reduction (P < 0.0001) in statin and nonstatin users. Conclusions: Our findings suggest that in overweight/obese diabetic persons, ILI and statin therapy may have substantial additive anti-inflammatory benefits.

UR - http://www.scopus.com/inward/record.url?scp=84879342248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879342248&partnerID=8YFLogxK

U2 - 10.1002/oby.20431

DO - 10.1002/oby.20431

M3 - Article

C2 - 23512860

AN - SCOPUS:84879342248

VL - 21

SP - 944

EP - 950

JO - Obesity

JF - Obesity

SN - 1930-7381

IS - 5

ER -